Prolepsia forecastYes / no

Will the FDA's Center for Drug Evaluation and Research approve more than 50 novel drugs in 2027?

As of 15 November 2026, Prolepsia puts the chance of yes at 42%.

42%chance of yes

Yes 42%No 58%
Prolepsia forecast made

How Prolepsia reasons

The report Prolepsia wrote with this forecast.

How forecasts are made · Track record

TL;DR

The forecast is 41.9% for Yes and 58.1% for No. The balance favors 50 or fewer qualifying approvals, but exceeding 50 remains a substantial possibility: recent approval levels sit close to the cutoff, and current activity is strong.

Key evidence

  • History puts the threshold just above the recent norm. CDER averaged 49.3333 novel approvals annually during 2017–2025, and three of those nine years exceeded 50. The broader 2015–2025 record also contains only three years above the threshold. Neither window establishes a sustained upward trend. (FDA historical report; FDA approval compilation)
  • Current throughput is healthy. As of November 15, the published 2026 list contains 48 approvals, with its latest entry dated November 9. That supports confidence in ongoing review activity, not a guaranteed level for the following year. (FDA 2026 list)
  • Forward indicators disagree. Preliminary broad NDA/BLA filings rose from 157 in FY2025 to 172 in FY2026. Separately, FDA’s planning projection puts original CDER applications at 131 in FY2027, versus 145 actual in FY2025. These populations differ, and neither equals calendar-year novel approvals. (Filing report; planning notice)
  • Faster reviews can redistribute approvals across years. Orforglipron was approved in April 2026 despite a January 2027 target date. Strong current-year totals therefore need not imply sustained growth next year. (FDA announcement)

Uncertainties

The largest gap is a complete, deduplicated list of qualifying 2027 applications and resubmissions. Public pipeline calendars mix novel drugs with supplements, previously approved ingredients and products outside CDER’s jurisdiction.

Review capacity is another uncertainty. Staffing losses raise concerns, while strong observed approvals argue against assuming a proportional decline in output. Manufacturing problems, review extensions and accelerated decisions can move individual drugs across the calendar boundary. Exactly 50 approvals resolves No, so a small number of timing changes can determine the outcome.

Read the full report

TL;DR

The forecast is 41.9% for Yes and 58.1% for No. Use 50 or fewer qualifying approvals as the more likely outcome, not as a secure result. The decisive point is that strong 2026 activity does not establish a lasting increase above the recent approval level.

Context

This question counts distinct novel drugs originally approved by CDER during calendar 2027. It includes qualifying new molecular entities and new therapeutic biologics, but excludes generics, biosimilars, supplemental indications and products regulated exclusively by other FDA centers. The relevant category is narrower than total FDA drug approvals or total original applications. (FDA novel-drug index) Exactly 50 resolves No; at least 51 resolves Yes. Original approval dates, rather than announcement or launch dates, determine the year.

As of November 15, 2026, the published current-year list contains 48 approvals, ending with an approval dated November 9. That is strong activity with part of the year remaining. It is not the final annual total, and none of those approvals counts toward 2027. (FDA 2026 list)

Evidence

The historical record is the backbone of the forecast. Recent approval levels sit near the threshold, but exceeding it has not been routine. During 2017–2025, annual approvals averaged 49.3333, with a sample standard deviation of 6.2849. Three of those nine years exceeded 50. The longer 2015–2025 window averaged 46.455, again with only three years above 50. These observations support a competitive outcome with a lean toward No, rather than a confident prediction on either side. (FDA historical report; FDA compilation)

The full annual history available here runs from 2000 through 2025. The older observations provide context, but the recent period is more comparable to the target year. Earlier figures were extracted from FDA’s compilation and were not separately reconciled against every annual report. Historical changes in biologics jurisdiction also limit direct comparisons across the whole period. (FDA compilation)

Year Novel approvals
2000 29
2001 29
2002 23
2003 27
2004 36
2005 20
2006 22
2007 18
2008 25
2009 26
2010 21
2011 30
2012 39
2013 27
2014 41
2015 45
2016 22
2017 46
2018 59
2019 48
2020 53
2021 50
2022 37
2023 55
2024 50
2025 46

Source: FDA approval compilation, with recent totals cross-checked against the historical annual report.

The table shows why the choice of historical window matters. The low 2016 count pulls down the longer-period average and raises its variability. But removing older weak years does not reveal a clear recent growth trend. The record instead shows repeated movement around the threshold, including two years that ended at exactly 50. Those years are reminders that a productive approval year can still resolve No. (FDA historical report)

Current throughput is the strongest positive evidence. The published 2026 list has 48 approvals, and FDA separately announced pimicotinib’s November 10 approval. The latter illustrates that a running list can lag individual announcements. It does not settle the final classification or annual total. The right inference is that review activity remains productive, not that 2027 inherits a minimum approval count. (FDA 2026 list)

Application supply gives a mixed signal. Preliminary broad NDA/BLA filings increased from 157 in FY2025 to 172 in FY2026. This supports a healthy flow of applications. But the figures include non-novel products and applications outside the exact scope of this question. A rise in this total cannot be translated directly into a rise in CDER novel approvals. (FDA filing report)

The counterweight is FDA’s July 30, 2026 planning projection: 131 original CDER NDA/BLA applications for FY2027, compared with 145 actual in FY2025. At the same time, projected active commercial investigational-drug workload rises from 10,215 to 10,715. A growing development pipeline can therefore coexist with fewer projected original applications in the near term. These are resource-planning measures, not a forecast of qualifying approvals, and fiscal years do not match the question’s calendar year. (FDA planning notice)

Capacity also cuts both ways. CDER’s workforce remained 1,083 employees below its opening FY2025 level at the end of FY2026, although FY2026 itself recorded a net gain of 10. These are center-wide employee counts, not productive novel-drug reviewer capacity. The staffing loss is a real constraint; the strong approval pace is evidence against treating it as an automatic, proportional fall in output. (FDA hiring data)

Funding does not resolve that tension. FDA’s planning notice includes operating reserves and a hiring-and-retention adjustment, while finance discussions warn that paid staffing measures can include administrative leave and severance. Money available and payroll paid are not the same as specialist review capacity. PDUFA reauthorization also matters because current authority expires in September 2027, leaving the final quarter of the target year exposed to renewal risk. None of this establishes an approval slowdown. (Planning notice; FDA finance minutes)

Individual review dates show why calendar effects deserve attention. Orforglipron was approved on April 1, 2026, ahead of its January 20, 2027 target. In the opposite direction, zanzalintinib’s target moved from December 3, 2026 to March 3, 2027. The first is a completed approval brought forward; the second is only a potential approval pushed into the target year. They do not establish a net gain for 2027. (FDA announcement; Exelixis filing)

Policy changes supply no dependable numerical uplift. The priority-voucher program advertises faster review, but its totals include products that do not qualify here. Reuters reported that the program had effectively been shelved; HHS disputed that account and said it remained ongoing. The evidence supports uncertainty about the durability of acceleration, not a confirmed shutdown or a permanent jump in novel approvals. (FDA program description; Reuters report)

What's non-obvious

Faster review can strengthen one year by borrowing from the next. An early approval creates real value for patients, but it does not necessarily increase the number of distinct drugs approved across adjacent years. The documented move of orforglipron from a 2027 target into 2026 makes this more than a theoretical concern. Reading the strong current-year pace as a durable increase would miss that distinction. (FDA announcement)

The other trap is counting the wrong population. Applications, regulatory actions, launch candidates and unique novel drugs are different things. Public calendars can include supplements, previously approved ingredients and out-of-scope therapies. Likewise, an on-time review action can be a complete response rather than an approval. I read the evidence as supporting a healthy but incompletely measured pipeline, not a verified surge in qualifying 2027 products. (FDA performance report)

Uncertainties

The largest gap is a complete, novelty-screened and deduplicated 2027 application cohort. That inventory would need to include resubmissions, likely later filings, review-center assignments and realistic decision windows. Its absence is not evidence that the pipeline is small. It limits how strongly the positive pipeline examples can support Yes.

Manufacturing remediation, clinical-review outcomes and major amendments can shift decisions across year-end. Actual reviewer productivity is also unknown: center-wide staffing and spending do not reveal the availability of the specific teams needed for each application. A complete cohort paired with mature review-performance data would close more of the gap than another broad industry calendar.

There is also a historical reporting discrepancy: one later FDA chart labels 2023 as 54, while the dedicated annual evidence and compilation give 55. The analysis retains 55; either figure leaves that year above the threshold. (FDA annual report; FDA compilation) The larger uncertainty remains future application outcomes and timing. That supports the saved balance of 41.9% for Yes and 58.1% for No.

Forecast history

How Prolepsia’s forecast has movedOne forecast so far: 42% on 15 Nov 2026.
DateForecast
42% chance of yes

Sources Prolepsia read

  1. Novel Drug Approvals at FDA | FDAwww.fda.gov
  2. Federal Register, Volume 91 Issue 145 (Thursday, July 30, 2026)www.govinfo.gov
  3. Form 10-Q for Exelixis INC filed 10/29/2026ir.exelixis.com
  4. Exclusive-US FDA shelves commissioner’s voucher program for speedy drug reviews, sources say By Reuterswww.investing.com
  5. Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day - Praxis Precision Medicines, Inc.investor.praxismedicines.com
  6. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights | Dyne Therapeutics, Inc.dynetx.gcs-web.com
  7. Q3 2026 Financial and Corporate Update Presentationinvestor.incyte.com
  8. PDUFA Dates 2027: 37 FDA Decision Dates Already Set | pdufa.biowww.pdufa.bio
  9. public-inspection.federalregister.govpublic-inspection.federalregister.gov
  10. Recent and anticipated novel drug approvals (3Q 2026 through 2Q 2027) - PubMedpubmed.ncbi.nlm.nih.gov

The question

This question asks whether the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) will approve at least 51 novel drugs during the 2027 calendar year, from January 1, 2027, through December 31, 2027, inclusive. The count will follow the FDA's official definition of novel drug approvals, encompassing new molecular entities (NMEs) and new therapeutic biological products that have not previously been approved or marketed in the United States. Historically, CDER's annual novel drug approval count has fluctuated considerably. Between 2015 and 2024, CDER approved an average of approximately 47 novel drugs annually, including 59 in 2018, 53 in 2020, 55 in 2023, and 50 in 2024. In 2025, CDER approved 46 novel drugs, comprising 34 NMEs and 12 therapeutic biologics. As of November 15, 2026, the FDA's published 2026 novel drug approval list contains 48 approvals, with additional approvals possible before the end of the year. These figures demonstrate that exceeding 50 annual approvals is historically achievable but not guaranteed. The question concerns the number of distinct novel drugs approved by CDER in 2027, rather than the total number of FDA drug approvals, which also includes generics, biosimilars, new formulations, and additional indications for previously approved drugs. Background sources include the FDA's Novel Drug Approvals at FDA page (https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda), its 2025 annual approval report, and its published 2026 approval list. ([fda.gov](https://www.fda.gov/files/drugs/published/new-drug-therapy-2025-annual-report.pdf?trk=article-ssr-frontend-pulse_little-text-block))

How it resolves

The question resolves YES if CDER officially reports approving 51 or more novel drugs with original FDA approval dates between January 1, 2027, and December 31, 2027, inclusive. It resolves NO if CDER reports 50 or fewer novel drug approvals during that period. The primary resolution source will be the FDA's official 'Novel Drug Approvals for 2027' webpage, expected to be accessible through the FDA's Novel Drug Approvals at FDA index (https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda). The FDA's annual 'Advancing Health Through Innovation: New Drug Therapy Approvals 2027' report, if published, will serve as a secondary source for confirmation. If the webpage and annual report disagree, the annual report's explicitly stated calendar-year novel drug approval total will take precedence, provided the discrepancy is not subsequently corrected by the FDA. If neither source provides a definitive count, the outcome will be determined using the FDA's official Compilation of CDER New Molecular Entity Drug and New Biologic Approvals, supplemented where necessary by Drugs@FDA approval records, applying the FDA's classification of novel drugs. The count will include new molecular entities approved through New Drug Applications (NDAs) and novel therapeutic biological products approved through Biologics License Applications (BLAs) under CDER's jurisdiction. Products regulated exclusively by other FDA centers, such as the Center for Biologics Evaluation and Research (CBER), will not count. Each distinct novel drug will count once, regardless of the number of approved indications or subsequent regulatory actions. Only original approvals with FDA approval dates falling within the 2027 calendar year will count, even if the public announcement occurs later. Resolution should occur after the FDA publishes its final 2027 annual approval figures, ordinarily during 2028. If the FDA does not publish a definitive annual total, resolution may proceed using complete official approval records once reasonably available. If no reliable official information sufficient to determine whether the threshold was exceeded is available by December 31, 2029, the question will be annulled rather than assigned an unsupported YES or NO outcome.

Fine print

The threshold is strictly greater than 50: exactly 50 approvals resolves NO, while 51 or more resolves YES. Accelerated approvals count if they represent qualifying novel drug approvals included in CDER's official annual tally. Emergency Use Authorizations, investigational permissions, generic approvals, biosimilar approvals, supplemental approvals for new indications, and approvals of new formulations of previously approved drugs do not count unless the FDA explicitly classifies the product as a novel drug in its annual tally. Approvals granted before January 1, 2027, or after December 31, 2027, do not count, even if an application was reviewed primarily during 2027. Drugs approved in 2027 that are subsequently withdrawn, discontinued, or subjected to additional safety restrictions will still count, provided their original approvals remain recognized in the FDA's historical 2027 novel drug approval tally. If a previously recorded approval is formally invalidated or removed from the historical tally before resolution, the corrected FDA count will be used. Changes to FDA organizational structure or reporting conventions should not automatically change the intended scope: the question concerns products that would qualify for CDER's historical novel drug approval count under the methodology in use when the question was formulated. The FDA's official classification takes precedence over independent industry estimates. The applicable calendar year is determined by FDA approval dates, not announcement dates or commercial launch dates.